Den europeiske union - latvisk - EMA (European Medicines Agency)

astrazeneca ab - benralizumabs - astma - zāles obstruktīvu elpceļu slimību, - fasenra ir norādīts, kā pievienot uz tehniskās apkopes ārstēšana pieaugušiem pacientiem ar smagu eosinophilic astmas nepietiekami kontrolē, neskatoties uz lielu devu inhalējamo kortikosteroīdu plus ilgstošas darbības beta agonistus.

Den europeiske union - islandsk - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - astma - lyf til veikindi öndunarvegi sjúkdómum, - fasenra er ætlað sem bæta á viðhald meðferð í fullorðinn sjúklinga með alvarlega eósínófíl asma ekki nægilega stjórnað þrátt fyrir hár-skammt andað krefur plús langverkandi beta örvum.

Den europeiske union - dansk - EMA (European Medicines Agency)

astrazeneca ab - benralizumab - astma - medicin for obstruktiv sygdomme, - fasenra er angivet som en tilføjelse om vedligeholdelse behandling hos voksne patienter med svær eosinofil astma, der ikke er tilstrækkeligt kontrolleret på trods af høje doser af inhalerede corticosteroider plus en langtidsvirkende β-agonister.

Israel - engelsk - Ministry of Health

kamada ltd, israel - bevacizumab - concentrate for solution for infusion - bevacizumab 25 mg/ml - bevacizumab - - bevacizumab kamada in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.- bevacizumab kamada in addition to platinum - based chemotherapy is indicated for first - line treatment of patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology. - bevacizumab kamada in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and /or metastatic renal cell cancer.- bevacizumab kamada in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.- bevacizumab kamada as a single agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.- bevacizumab kamada in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at high risk for recurrence (residual disease after debulking).- bevacizumab kamada in combination with carboplatin and gemcitabine, is indicated for the treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor-targeted agents.- bevacizumab kamada in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents - bevacizumab kamada in combination with paclitaxel and cisplatin or paclitaxel and topotecan is indicated for treatment of patients with persistent, recurrent, or metastatic carcinoma of the cervix.- bevacizumab kamada in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations.

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - bevacizumabum - concentrato per soluzione per infusione - bevacizumabum 100 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 5.44 mg. - onkologikum - biotechnologika

Sveits - italiensk - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - bevacizumabum - concentrato per soluzione per infusione - bevacizumabum 400 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 16 ml corresp. natrium 21.76 mg. - onkologikum - biotechnologika

Sveits - fransk - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - bevacizumabum - solution à diluer pour perfusion - bevacizumabum 100 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 5.44 mg. - onkologikum - biotechnologika

Sveits - fransk - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - bevacizumabum - solution à diluer pour perfusion - bevacizumabum 400 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 16 ml corresp. natrium 21.76 mg. - onkologikum - biotechnologika

Sveits - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - bevacizumabum - konzentrat zur herstellung einer infusionslösung - bevacizumabum 100 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 4 ml corresp. natrium 5.44 mg. - onkologikum - biotechnologika

Sveits - tysk - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - bevacizumabum - konzentrat zur herstellung einer infusionslösung - bevacizumabum 400 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 16 ml corresp. natrium 21.76 mg. - onkologikum - biotechnologika